Burrows Scott L sold $1.3M of SYRE
Burrows Scott L (Chief Financial Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.13 ($87.12–$87.14, $1.31M total) across 2 trades on 2026-06-25.
How this was made
The 30-second read
Why it matters
The disclosure may slightly affect sentiment, but it does not introduce new operational or financial information for SYRE.
Market read
Traders may monitor insider activity, but this specific Form 4 does not provide a new fundamental catalyst.
What to watch
The filing lacks motivation (taxes, diversification, planned spending) and does not quantify total insider ownership change beyond the post-transaction share count.
Background
The article reports an SEC Form 4 insider transaction by Spyre Therapeutics’ CFO.
Ticker impact
Spyre Therapeutics CFO Burrows Scott L sold 15,000 shares in open-market transactions at about $87.13 (Form 4).
Likely limited near-term impact; any effect would be sentiment-driven and typically modest for routine Form 4 sales.
The article is a primary SEC Form 4 disclosure with transaction details, but it does not include earnings, guidance, regulatory, or operational changes that would reprice the business.
Market effects
No sector read-across; this is a single-company insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
CFO sales can be routine liquidity/compensation-related and may not signal reduced confidence, especially without a 10b5-1 plan or additional context.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderBurrows Scott L
CFO who sold 15,000 shares in open-market transactions.
